SILVER SPRING, Md.-- Specialty drugmaker United Therapeutics Corp. said Monday that it received a subpoena from federal regulators looking into the company's marketing of three drugs used to treat a form of hypertension. United Therapeutics said it intends to cooperate with the investigation. United Therapeutics shares fell 31 cents to $90.66 in trading.» Read More
GlaxoSmithKline's Alli (pronounced "ally" -- don't ask me why they put an "i" at the end) is the new over-the-counter version of prescription Xenical from Roche. It's a diet pill, but as I previously blogged, it has potentially embarrassing side effects. On the plus side, GSK says you can subtract 50% more pounds if you use Alli as directed. But, if you still eat too many fatty foods, you could run into trouble.
Here's our latest contest "stock report." Dow Jones certainly proved a big winner with the unsolicited takeover bid by Rupert Murdoch. But DJ wasn't the only stock benefiting from M&A talk--as you can see. Meanwhile, earnings took their toll on the worst performers. There's a couple of new names (MOVE, ENTG) on the most active list--while the widely helds remained the same.
Merck, Germany's drugs and chemicals group, received four final bids for its generics drugs business, sources familiar with the situation said on Monday.
So, as expected, Bristol-Myers Squibb posted its SEC filing with the employment terms for new CEO Jim Cornelius last Friday evening. On a conference call with reporters on Thursday, The New York Times' Stephanie Saul asked Chairman Jim Robinson if the drug company would continue paying $25,000 a month for Cornelius' Manhattan pad. He responded by saying that the terms of his employment would be disclosed in the SEC filing the following day but added, "I think you'll be pleased."
Analysts have projected peak sales of up to $1 billion a year for the allergy treatment, which is chemically known as fluticasone furoate.
The decision was widely expected, after a panel of FDA advisers two weeks ago voted 20-1 against approving the drug, Arcoxia.
Hey folks, we have some info on the weekly leader we can pass along. At this point, the current weekly leader is Alejandro Garcia--tracking at about a 90% gain and is currently all in cash. He has made two trades this week. (This is not to declare ANYONE a weekly winner yet)
Bristol-Myers Squibb announced today a potential $1 billion partnership deal with the biggest pharmaceutical company in the world, Pfizer, on a clot-busting drug. And there are signals that its older, troubled partnership with ImClone Systems could be in for some reconciliation.Shares of IMCL were down after the company reported that sales of the cancer drug it markets with BMY, Erbitux, climbed 16% in the first quarter, but fell short of the analyst consensus by $5 million.
Swiss-based Roche said it was cutting production of influenza drug Tamiflu, seen as one of the best defenses against a possible bird flu pandemic, because supply now exceeds demand.
Is this a sign that the world has become complacent about the pandemic flu threat? Or that some people think it was all a bunch of hooey?Roche today is announcing that it's cutting back production of Tamiflu. When bird flu stories and fears started reaching critical mass more than a year ago, Roche came under considerable criticism for not being able to make enough Tamiflu to meet the sudden spike in demand.
Chemical and pharmaceutical maker Bayer on Thursday reported a surge in first-quarter net profit to 2.8 billion euros ($3.82 billion), boosted by one-time gains and strong sales.
Eli Lilly announced Wednesday it has received approval from the FDA to market Reconcile, the first selective serotonin reuptake inhibitor (SSRI) class of antidepressants approved by the FDA for treatment of canine separation anxiety in conjunction with behavior modification training.
GlaxoSmithKline profits dipped 1% in the first quarter, as sales were hit by the strength of sterling and the loss of patent protection on key medicines, Europe's biggest drugmaker said on Wednesday.
Here's our re-cap of today with the leaderboard, most active and widely held as well as the trivia questions. (we have video of all this below). The video question is worth $2,000 Bonus Bucks: According to the Alix Partners brand survey, which company was voted the least trusted brand in America? Your selection of answers is: Microsoft or Kraft or Ford or Sony.
Several other major drug companies were apparently interested in buying MedImmune, including Merck, Eli Lilly and possibly Novartis, CNBC’s David Faber reported Tuesday.
Here's a look at the latest contest stock action. Mergers and acquisitions played a strong part in the best performers (MedImmune, Baush & Lomb) as well as earnings figures (Angiodynamics). A couple of newer names showed up in the most active list (Ligand and Angiotech) while the widely held stocks stayed the same.
A bidding war for Alliance Boots ended Tuesday with the company's deputy chairman and a private equity firm emerging the winner after a sweetened 11 billion pound ($22 billion) offer pushed a rival private equity group out of the running.
Amgen, the world's largest biotechnology company, reported higher first-quarter profit on Monday, driven by increased sales of its anemia and arthritis drugs. Excluding items, the Thousand Oaks, Calif.-based company earned $1.08 a share, matching analysts' average forecast of $1.08 a share, according to Thomson Financial.
M&A news and earnings updates provided some of the catalysts for Monday's most actively traded stocks.
AstraZeneca has agreed to buy U.S. biotechnology company MedImmune for more than $15 billion in the biggest transaction since the creation of the Anglo-Swedish drugs group in 1999.